8 citations
,
December 2008 in “Journal of The American Academy of Dermatology” Finasteride can cause a unique skin reaction on the penile shaft.
April 2011 in “한국생물공학회 학술대회” Lotion with fucoidan from brown seaweed improved skin and reduced allergy symptoms in mice with dermatitis.
82 citations
,
March 2013 in “PLoS ONE” Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.
December 2021 in “Daehanhanuihakoeji” The traditional herbal formulas Yongdamsagan-Tang and Paljung-san, along with the drug finasteride, can reduce inflammation and may work together without affecting each other's effectiveness against benign prostatic hyperplasia.
3 citations
,
August 2014 in “Steroids” Fermentation of Finasteride with Ocimum sanctum L. creates new metabolite that inhibits tyrosinase.
4 citations
,
January 2023 in “Journal of Clinical Investigation” Specific mutations in a receptor cause facial abnormalities and hair loss.
July 2025 in “bioRxiv (Cold Spring Harbor Laboratory)” A new Wnt surrogate specifically targets the Frizzled7 receptor, promoting organoid formation and hair growth.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
4 citations
,
January 2025 in “JAAD reviews.” Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.
April 2025 in “Journal of Investigative Dermatology” Fibronectin is essential for hair follicle regeneration by supporting stem cells.
17 citations
,
April 2006 in “Brain Research” 5α-reduced neurosteroids may help regulate glial cell differentiation.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
Antimalarial agents are effective for LPP, and intralesional steroids are effective for FFA.
14 citations
,
June 1995 in “The Journal of Clinical Endocrinology and Metabolism”
166 citations
,
April 2012 in “Journal of The American Academy of Dermatology” Mostly postmenopausal Caucasian women get Frontal Fibrosing Alopecia, which often includes eyebrow loss and has limited treatment success.
4 citations
,
September 2018 in “The Journal of Dermatology” A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.
January 2008 in “xPharm: The Comprehensive Pharmacology Reference” July 2013 in “Pharmaceutical Regulatory Affairs Open Access” Formulation F1 is the best for delivering finasteride effectively.
26 citations
,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
March 2026 in “Korean Journal of Clinical Pharmacy” In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.
April 2016 in “The FASEB Journal” Blocking androgen receptors early in life increases estrogen levels and reduces sexual motivation in male rats.
1 citations
,
December 2023 in “Journal of the European Academy of Dermatology and Venereology” January 2005 in “Psychoneuroendocrinology” Finasteride may affect brain chemistry and behavior, offering potential for treating certain mental health conditions.
Knocking out the FGF5 gene in sheep increased wool production and hair-follicle density.
3 citations
,
January 2024 in “Liver International” Targeting thyroid hormone receptor α in liver cells may help treat liver fibrosis.